ClinicalTrials.gg
TerminatedNCT03483948Updated Nov 20, 2019

Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

A Phase 1 interventional study of HMPL-523 and Azacitidine in Acute Myeloid Leukemia, sponsored by Hutchison Medipharma Limited. Terminated at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-11-20.

Sponsored by Hutchison Medipharma Limited (part of HUTCHMED) · Phase 1, Interventional, and Treatment

Why this study was terminated
Slow Enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Enrollment
403rd of 433
7 · median 50
Started
2018
with 26 others
Phase 1
121 of 473
69 open now
Registered
61st of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 403rd largest by enrollment of the 433 interventional ones that give a count, is one of 27 that started in 2018, is one of 121 in phase 1, and was the 61st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

260 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This is a Phase I, open-label, non-randomized, multicenter study to evaluate the safety, pharmacokinetics and preliminary efficacy of HMPL-523 in combination with Azacitidine in previously untreated elderly patients with AML who are not eligible for standard induction therapy.

Read the detailed description

There are two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2).

Dose-escalation stage (stage 1):

The conventional 3+3 design (3 patients per dose cohort, with the potential to add additional 3 patients to the same cohort to further evaluate toxicity) will be applied for dose escalation and maximum tolerated dosage determination. Approximately 12 to 18 dose limited toxicities evaluable patients will be enrolled. A dose of HMPL-523 up to 800mg will be taken orally once daily continuously through a 28-day Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.

Dose-expansion stage (stage 2):

This phase is to further evaluate the safety, pharmacokinetics and preliminary efficacy of HMPL-523 in combination with Azacitidine in approximately 28 previously untreated elderly patients with AML. Patients will receive HMPL-523 in combination with Azacitidine in a 28-day cycle continuously until disease progression/relapse, death, or intolerable toxicity, whichever comes first.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must have confirmation of AML by WHO criteria, except for APL (M3)
  2. Subject must be ≥ 65 years of old and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidity or other factors
  3. Subject must have received no prior treatment for AML with the exception of hydroxyurea
  4. performance status of 0-1. For dose-expansion stage, ECOG PS of 2 will also be eligible

Exclusion criteria

Exclusion Criteria:

  1. Subject has received treatment of hypomethylating agent and/or chemo therapeutic agent for MDS or MPN
  2. Subject has known active CNS involvement or extramedullary sarcoma from AML
  3. Subject has favorable risk cytogenetics as categorized by the NCCN Guidelines Version 1, 2018 for Acute Myeloid Leukemia, such as inv(16) or t(16;16) or t(8;21) or t(15;17)
  4. Subject has a white blood cell count > 25 × 109/L (Hydroxyurea is permitted to meet this criterion)
  5. Subject with serum amylase or lipase > the
  6. Subject is known to be positive for or C infection with the exception of those with an undetectable viral load.
  7. Subject who don't have enough liver or renal function
  8. Subject with (NYHA) Class III or greater congestive heart failure
  9. Subject received herbal therapy ≤ 1 week prior to initiation of study treatment
  10. Subject received prior treatment with any SYK inhibitors (Fostamatinib) or FLT3 inhibitor (Quizartinib) or multi-target inhibitor with SYK or FLT3 inhibition activity (Midostaurin)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    HMPL-523 & Azacitidine

    HMPL-523 will be taken orally once daily continuously through a 28-days Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.

    Drug: HMPL-523 · Drug: Azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Event (AE) monitoring of HMPL-523 in combination with azacitidine

    AE monitoring will be assessed by evaluation of study drug exposure, AEs , serious AEs, all deaths, as well as laboratory determinations and vital sign parameters.

    Time frame: Measured from the first dose to within 30 days after the last dose.

  2. Overall response rate (ORR)

    Overall response rate will be defined as the proportion of subjects who achieve a complete remission (CR), complete remission incomplete (CRi), Morphologic leukemia-free state (MLFS), or partial remission(PR) per 2017 European Leukemia Net (ELN) recommendations

    Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of HMPL-523

    Maximum concentration, occurring at Tmax.

    Time frame: Measured on the cycle 1 day 7, cycle 1 day 8, cycle 1 day 28 and cycle 2 day 1.

  2. The time to Cmax (peak time, Tmax) of HMPL-523

    The time at which maximum plasma concentration (Cmax) is observed.

    Time frame: Measured on the cycle 1 day 7, cycle 1 day 8, cycle 1 day 28 and cycle 2 day 1.

  3. The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) of HMPL-523

    The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration.

    Time frame: Measured on the cycle 1 day 7, cycle 1 day 8, cycle 1 day 28 and cycle 2 day 1.

  4. Half-life (t1/2) of HMPL-523

    The time required for the concentration of the drug to reach half of its original value.

    Time frame: Measured on the cycle 1 day 7, cycle 1 day 8, cycle 1 day 28 and cycle 2 day 1.

  5. Clearance (CL) of Azacitidine

    Clearance is defined as the rate at which drug is cleared from the blood.

    Time frame: Measured on the cycle 1 day 7 and Cycle 1 day 8.

  6. The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) of Azacitidine

    The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration.

    Time frame: Measured on the cycle 1 day 7 and Cycle 1 day 8.

  7. Half-life (t1/2) of Azacitidine

    The time required for the concentration of the drug to reach half of its original value.

    Time frame: Measured on the cycle 1 day 7 and Cycle 1 day 8.

  8. Steady-state concentration(Css) of Azacitidine

    The average concentration of drug at steady state

    Time frame: Measured on the cycle 1 day 7 and Cycle 1 day 8.

  9. Complete Remission Rate of Minimal Residual Disease (MRD) Negativity (CR MRD- rate)

    CR MRD- rate will be defined as the proportion of subjects who achieve a CR and has a negative RT-qPCR or MFC at the same time.

    Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.

  10. Event Free Survival (EFS)

    EFS will be defined as the number of days from the date of first dose to the date of earliest recurrence or PD or death.

    Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.

  11. Disease-free Survival (DFS)

    DFS will be defined as the number of days from the date of composite complete response (CR + CRi) to the date of earliest recurrence or death.

    Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.

  12. Overall Survival (OS)

    OS will be defined as the number of days from the date of enrollment to the date of death.

    Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.

  13. Cumulative incidence of relapse (CIR)

    CIR will be defined as the cumulative proportion of subjects who has relapsed after achieving a composite complete response (CR + CRi).

    Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.

07

Study locations

1 site
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
    Tianjin, Tianjin 300020, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Sep 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Mar 30, 2018
StartActual
Oct 9, 2018
Primary completionActual
Sep 9, 2019
CompletionActual
Sep 9, 2019
Last update
Nov 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03483948
Responsible party
Sponsor
First posted
Mar 30, 2018
Start date
Oct 9, 2018
Primary completion
Sep 9, 2019
Completion
Sep 9, 2019
Last update
Nov 20, 2019

Study contacts

Jianxiang Wang, Prof.
principal investigator · Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovleplenib

Start the discussion